Press Releases

Receive E-mail Alerts
21 November 2019 at 7:00 AM EST
Summary ToggleProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Orphan Drug designation
18 November 2019 at 7:23 AM EST
Summary ToggleProQR to Present at Upcoming Scientific Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Company management
13 November 2019 at 7:00 AM EST
Summary ToggleProQR to Present at Upcoming Investor Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Company management
6 November 2019 at 7:00 AM EST
Summary ToggleProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020 QR-1123 Investigational New Drug application active for autosomal dominant retinitis pigmentosa €49.3 million net
18 October 2019 at 8:20 AM EDT
Summary ToggleProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previously
15 October 2019 at 11:17 PM EDT
Summary ToggleProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the pricing of its
15 October 2019 at 4:13 PM EDT
Summary ToggleProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it intends to
15 October 2019 at 4:08 PM EDT
Summary ToggleProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediatric Disease
10 October 2019 at 6:00 AM EDT
Summary ToggleProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
  Reported rapid, significant and durable improvements in vision at twelve months   Concordant improvement in key secondary outcome measures   The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile   Strengthens confidence in the ongoing Phase 2/3
7 October 2019 at 7:00 AM EDT
Summary ToggleProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will present and discuss
30 September 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at Two Investor Conferences in October
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company
9 September 2019 at 7:00 AM EDT
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast
12 August 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.
7 August 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Financial Results for the Second Quarter of 2019
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for
29 July 2019 at 7:00 AM EDT
Summary ToggleEuropean Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
Access based on positive interim analysis of clinical data as well as preclinical data to date  PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval ProQR believes that the EU will represent an important market
2 July 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
LEIDEN, Netherlands and CAMBRIDGE, Mass. , July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced an upcoming presentation
3 June 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the JMP Securities Life Sciences Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company
15 May 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the RBC Capital Markets Healthcare Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that management will
8 May 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Financial Results for the First Quarter of 2019
LEIDEN, Netherlands & CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for the
22 April 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at Three Scientific Conferences in April
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the Annual General
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
LEIDEN, Netherlands & CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, has nominated Bart Filius , Chief
15 April 2019 at 7:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
LEIDEN, The Netherlands and CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient
1 April 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the H.C. Wainwright Global Life Sciences Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that management will
26 March 2019 at 4:01 PM EDT
Summary ToggleProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the strategic spin out
11 March 2019 at 4:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed
5 March 2019 at 7:00 AM EST
Summary ToggleProQR to Present at Cowen Health Care Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the management will
27 February 2019 at 7:00 AM EST
Summary ToggleProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
LEIDEN, The Netherlands & CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results
29 January 2019 at 8:30 AM EST
Summary ToggleProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
LEIDEN, the Netherlands & CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and
7 January 2019 at 7:00 AM EST
Summary ToggleProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached
3 January 2019 at 7:00 AM EST
Summary ToggleProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY .
2 January 2019 at 7:00 AM EST
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track
24 December 2018 at 7:00 AM EST
Summary ToggleProQR Therapeutics Added to NASDAQ Biotechnology Index
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Dec. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that as of today the
17 December 2018 at 11:52 AM EST
Summary ToggleProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands and CAMBRIDGE, Mass. , Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a
13 December 2018 at 7:00 AM EST
Summary ToggleProQR Announces Strategic Changes to the Management Team and Key New Hires
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced changes to
10 December 2018 at 7:00 AM EST
Summary ToggleProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
LEIDEN, Netherlands and CAMBRIDGE, Mass. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it was awarded an
4 December 2018 at 7:00 AM EST
Summary ToggleProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.
20 November 2018 at 7:00 AM EST
Summary ToggleProQR to Present at the Evercore ISI HealthConX Conference
LEIDEN, the Netherlands , Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the management will give a
7 November 2018 at 7:00 AM EST
Summary ToggleProQR Announces Financial Results for the Third Quarter of 2018
LEIDEN, Netherlands and CAMBRIDGE, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced results
31 October 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming
29 October 2018 at 7:33 AM EDT
Summary ToggleProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
ProQR receives exclusive worldwide license for IONIS-RHO-2.5 Rx , now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in human Phase 1/2 clinical trial in adRP patients is expected to start in 2019 LEIDEN, the
2 October 2018 at 7:00 AM EDT
Summary ToggleProQR to Present at the Chardan Genetic Medicines Conference
LEIDEN, the Netherlands , Oct. 02, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company will give a presentation
24 September 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Presentations at the OTS Annual Meeting
LEIDEN, the Netherlands , Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the
11 September 2018 at 4:01 PM EDT
Summary ToggleProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the

7 September 2018 at 4:21 AM EDT
Summary ToggleProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the

5 September 2018 at 4:01 PM EDT
Summary ToggleProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that

5 September 2018 at 4:00 AM EDT
Summary ToggleProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events A Phase 2/3 pivotal trial is expected to start in the first half of 2019 Management to host a

15 August 2018 at 7:00 AM EDT
Summary ToggleProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th LEIDEN, The Netherlands and CAMBRIDGE, Mass. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

8 August 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Financial Results for the Second Quarter of 2018

LEIDEN, The Netherlands , Aug. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced results for the second

1 August 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

LEIDEN, the Netherlands , Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed

12 July 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

LEIDEN, the Netherlands , July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the

28 June 2018 at 7:00 AM EDT
Summary ToggleProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a first-in-class potential therapeutic RNA molecule designed to improve the healing and integrity of skin in
14 June 2018 at 7:00 AM EDT
Summary ToggleProQR to Present at the JMP Life Sciences Conference

LEIDEN, the Netherlands , June 14, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company will give a presentation

12 June 2018 at 7:00 AM EDT
Summary ToggleProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018 LEIDEN, the Netherlands , June 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of

4 June 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

LEIDEN, The Netherlands , June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the European

23 May 2018 at 7:00 AM EDT
Summary ToggleProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

LEIDEN, the Netherlands , May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.

9 May 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Results for the First Quarter of 2018

Key updates Eight out of twelve patients have been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with full data expected during 2019. ProQR and Galapagos N.V.

30 April 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

LEIDEN, the Netherlands , April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the Company will present at two

23 April 2018 at 7:00 AM EDT
Summary ToggleProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO

Key Updates Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled. The trial is on track to announce interim six-month data on safety, effects on vision and retinal structure in the second half of the year.

11 April 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders

LEIDEN, the Netherlands , April 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis 10, dystrophic

10 April 2018 at 7:00 AM EDT
Summary ToggleProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I editing, Dr. Beal will be instrumental in advancing the

3 April 2018 at 7:00 AM EDT
Summary ToggleProQR to Present at Two Upcoming Conferences

LEIDEN, the Netherlands , April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis 10, dystrophic

5 March 2018 at 7:00 AM EST
Summary ToggleProQR to Present at Upcoming Investor Conference
LEIDEN, the Netherlands , March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
28 February 2018 at 7:00 AM EST
Summary ToggleProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
Key updates Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase 1/2 safety & efficacy trial for QR-110 in children and adults with Leber’s
27 February 2018 at 7:00 AM EST
Summary ToggleProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
LEIDEN, the Netherlands , Feb. 27, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
12 February 2018 at 7:00 AM EST
Summary ToggleFoundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program
6 February 2018 at 7:00 AM EST
Summary ToggleProQR to Present at Upcoming Scientific Meeting and Investor Conference
LEIDEN, the Netherlands , Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
8 January 2018 at 7:00 AM EST
Summary ToggleProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
LEIDEN, the Netherlands , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG). Under the agreement the two companies will work together to discover novel
27 December 2017 at 7:00 AM EST
Summary ToggleProQR Announces Extraordinary General Meeting of Shareholders
LEIDEN, the Netherlands , Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018 , at 16:00 CET , at the offices of the Company at  Zernikedreef 9, 2333CK, Leiden, the
29 November 2017 at 7:00 AM EST
Summary ToggleProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA. QR-313 also received U.S. ODD from the FDA in September 2017 . QR-313 represents the fifth candidate in the company’s pipeline to receive ODD in the U.S.
21 November 2017 at 7:00 AM EST
Summary ToggleProQR to Present at the Annual Piper Jaffray Healthcare Conference
LEIDEN, the Netherlands , Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
20 November 2017 at 7:00 AM EST
Summary ToggleProQR Announces Results for the Third Quarter of 2017
Key updates Runway into the second half of 2019: cash of €39.7 million at end of Q3, increased by gross proceeds of approximately $20 million from an issuance of ordinary shares in November 2017 that will fund operations through potential clinical data readouts in three different programs.
14 November 2017 at 7:44 AM EST
Summary ToggleProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
LEIDEN, The Netherlands , Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the pricing of its
13 November 2017 at 4:01 PM EST
Summary ToggleProQR Announces Proposed Public Offering of Ordinary Shares
LEIDEN, the Netherlands , Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it intends to
13 November 2017 at 7:00 AM EST
Summary ToggleProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969 ) in children and adults with Leber’s congenital amaurosis 10 (LCA 10). LCA 10 is one of the most prevalent forms of gene-related blindness in children
9 November 2017 at 7:00 AM EST
Summary ToggleProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
Key Updates Dr. Thaddeus (Ted) Dryja , a pioneer in the field of retinal genetic diseases, joins the Company’s Scientific Advisory Board . Dr. Dryja will play a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The Netherlands , Nov.
31 October 2017 at 7:00 AM EDT
Summary ToggleProQR to Present at EuroTIDES Conference
LEIDEN, The Netherlands , Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
26 October 2017 at 7:00 AM EDT
Summary ToggleProQR Announces Management Change and Key Promotions
Key Updates Company announces departure of Noreen R. Henig , Chief Medical Officer, promotion of Peter Adamson to Senior Vice President Ophthalmology Franchise and Robert Friesen to Senior Vice President Science and Early Development . David M. Rodman , M.D., Chief Development Strategy Officer will
24 October 2017 at 7:00 AM EDT
Summary ToggleProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
LEIDEN, the Netherlands , Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
6 October 2017 at 7:00 AM EDT
Summary ToggleProQR to Present at the Chardan Inaugural Gene Therapy Conference
LEIDEN, the Netherlands , Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
25 September 2017 at 4:00 PM EDT
Summary ToggleProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment. A clinically meaningful improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a mean
21 September 2017 at 7:05 AM EDT
Summary ToggleProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
Key updates ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer ® RNA editing platform technology. Axiomer ® technology Editing Oligonucleotides (EONs) recruit endogenous ADAR to make single nucleotide changes to RNA in a
21 September 2017 at 7:00 AM EDT
Summary ToggleProQR to Present at Two Investor Conferences in September
LEIDEN, the Netherlands , Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of September. Cantor Fitzgerald Global Healthcare Conference On Tuesday, September 26, 2017 at 9:10am ET ,
19 September 2017 at 7:00 AM EDT
Summary ToggleProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA , representing the fifth program in the Company’s pipeline to receive ODD in the U.S. The Company will be presenting pre-clinical data for QR-313 at two European
12 September 2017 at 7:00 AM EDT
Summary ToggleProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders and will be entitled
5 September 2017 at 7:00 AM EDT
Summary ToggleProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the fourth in the broader pipeline to receive ODD in the U.S. and EU.
29 August 2017 at 7:00 AM EDT
Summary ToggleProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
Key Updates Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation. Top-line trial data are expected to be issued in a press release post-market close on Monday, September 25, 2017 , followed by a conference call.
28 August 2017 at 7:00 AM EDT
Summary ToggleProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board : Dr. Phil Zamore , Dr. Cy Stein and Dr. Scott Armstrong , who bring a tremendous amount of experience in the fields of RNA-based therapeutics and genetic pediatric diseases. The new members will join Dr.
16 August 2017 at 7:00 AM EDT
Summary ToggleProQR Announces Results for the Second Quarter of 2017
Key updates Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference .  Enrollment completed in the Phase 1b clinical trial in cystic fibrosis (CF) and top-line data expected to be announced in September. The Investigational New Drug Application (IND) and the
5 July 2017 at 7:01 AM EDT
Summary ToggleProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
Key Updates ProQR’s QRX-411 receives Orphan Drug Designation by the FDA and EMA for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is an inherited condition that is characterized by combined deafness and blindness.
15 June 2017 at 7:06 AM EDT
Summary ToggleProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
Key program features and updates: ProQR to host an R&D day in New York today, June 15 , from 8:00am to 1:00pm Eastern Standard Time . The live webcast can be accessed at www.proqr.com/rd-day . Cystic Fibrosis (CF): Full data from the nasal potential difference (NPD) study for QR-010, ProQR’s
13 June 2017 at 7:01 AM EDT
Summary ToggleProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
LEIDEN, The Netherlands , June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Daniel de Boer , Chief Executive Officer, will participate in a panel discussion focused on emerging treatment options in cystic fibrosis during the JMP Securities Life Science
8 June 2017 at 9:05 AM EDT
Summary ToggleProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
Key Updates An oral presentation on the final results from the proof-of-concept (PoC) nasal potential difference (NPD) trial will be given by Steve Rowe , MD at the European Cystic Fibrosis Society (ECFS) conference. Preliminary data from the Phase 1b study, PQ-010-001 single ascending dose (SAD)
31 May 2017 at 7:00 AM EDT
Summary ToggleProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
 Key Updates ProQR receives Fast Track designation by the U.S. Food and Drug Administration ( FDA ). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients with Leber’s Congenital Amaurosis Type 10 (LCA 10). LCA 10 is one of the most prevalent forms of
17 May 2017 at 7:00 AM EDT
Summary ToggleProQR Announces Results for the First Quarter of 2017
Key updates QR-010 Phase 1b clinical trial on track to present top-line data in cystic fibrosis (CF) patients in mid-2017. Investigational new drug (IND) application for QR-110, ProQR’s lead program in ophthalmology, was cleared by the FDA to start a clinical trial in both adult and pediatric LCA
15 May 2017 at 7:00 AM EDT
Summary ToggleProQR remembers co-founder Henri Termeer after his unexpected passing
LEIDEN, the Netherlands, May 15, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), remembers co-founder and supervisory board member Henri A. Termeer, who unexpectedly passed away Friday May 12, 2017 at age 71 at his house in Marblehead, MA.
9 May 2017 at 7:01 AM EDT
Summary ToggleProQR Announces R&D Day in New York on June 15
Key updates: ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ET Presentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313 for dystrophic epidermolysis bullosa (DEB) An update on the
1 May 2017 at 7:00 AM EDT
Summary ToggleProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical trials for this program in both adult and pediatric patients.
27 April 2017 at 7:01 AM EDT
Summary ToggleProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration ( FDA ), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10 (LCA 10) patients LCA 10 is one of the most prevalent forms of gene-related
20 April 2017 at 7:01 AM EDT
Summary ToggleProQR to Present at the Deutsche Bank Health Care Conference
LEIDEN, the Netherlands , April 20, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg , Chief Innovation Officer, will present at the 42 nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET .
10 April 2017 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders
LEIDEN, the Netherlands , April 10, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10, 2017 at 15:00 CET , at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the
3 April 2017 at 7:01 AM EDT
Summary ToggleProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
Key Updates ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033 QR-010 is currently being studied in 64 homozygous F508del patients in a Phase 1b safety, tolerability and exploratory efficacy trial.
27 March 2017 at 7:01 AM EDT
Summary ToggleProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
LEIDEN, the Netherlands , March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman , MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in translational medicine,
1 March 2017 at 7:01 AM EST
Summary ToggleProQR to Present at Two Upcoming Investor Conferences in March
LEIDEN, the Netherlands , March 01, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital
28 February 2017 at 7:01 AM EST
Summary ToggleProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
Key updates Major progress in the QR-010 development program for CF with presentation of positive clinical data at North American CF conference in October 2016 On track to report data from the ongoing Phase 1b trial of QR-010 in mid-2017 Finalizing preparations to start a Phase 1b/2 trial of QR-110
27 February 2017 at 7:00 AM EST
Summary ToggleOn a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
LEIDEN, the Netherlands , Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital
7 February 2017 at 7:01 AM EST
Summary ToggleProQR to Present at the LEERINK Partners Global Healthcare Conference
LEIDEN, the Netherlands , Feb. 07, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis
14 November 2016 at 7:01 AM EST
Summary ToggleProQR Announces Results for the Third Quarter of 2016
LEIDEN, the Netherlands , Nov. 14, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
27 October 2016 at 7:01 AM EDT
Summary ToggleProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients
Topline data to be presented today at NACFC LEIDEN, the Netherlands , Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
27 September 2016 at 7:00 AM EDT
Summary ToggleProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC
LEIDEN, the Netherlands , Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
6 September 2016 at 7:00 AM EDT
Summary ToggleProQR to Present at Scientific and Investor Conferences in September
LEIDEN, the Netherlands , Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
17 August 2016 at 7:00 AM EDT
Summary ToggleProQR Announces Results for the Second Quarter of 2016
LEIDEN, the Netherlands , Aug. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
19 July 2016 at 7:00 AM EDT
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
LEIDEN, the Netherlands , July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
21 June 2016 at 9:01 AM EDT
Summary ToggleProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
LEIDEN, the Netherlands , June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
1 June 2016 at 7:02 AM EDT
Summary ToggleProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
LEIDEN, the Netherlands , June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company’s investigational drug QR-110 has received orphan drug designation (ODD) from both the U.S.
1 June 2016 at 7:02 AM EDT
Summary ToggleProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference
LEIDEN, the Netherlands , June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
18 May 2016 at 7:01 AM EDT
Summary ToggleProQR Announces Results for the First Quarter of 2016
LEIDEN, the Netherlands , May 18, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
25 April 2016 at 4:01 PM EDT
Summary ToggleProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting
LEIDEN, Netherlands , April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
7 April 2016 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders
LEIDEN, the Netherlands , April 07, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
1 March 2016 at 7:01 AM EST
Summary ToggleProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference
LEIDEN, the Netherlands , March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amauros
17 February 2016 at 7:01 AM EST
Summary ToggleProQR Announces Results for the Fourth Quarter and Full Year 2015
LEIDEN, the Netherlands , Feb. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
3 February 2016 at 7:01 AM EST
Summary ToggleProQR to Present at the Leerink Partners Global Healthcare Conference
LEIDEN, the Netherlands , Feb.
30 November 2015 at 7:00 AM EST
Summary ToggleProQR Announces R&D Day and Provides Update on Innovation Portfolio
First Investor R&D Day on March 14, 2016 in New York, NY LEIDEN, Netherlands , Nov. 30, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
23 November 2015 at 6:30 AM EST
Summary ToggleProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
LEIDEN, The Netherlands, Nov.  23, 2015  (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
1 October 2015 at 7:00 AM EDT
Summary ToggleProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences
LEIDEN, Netherlands , Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
23 September 2015 at 7:00 AM EDT
Summary ToggleProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable
LEIDEN, the Netherlands , Sept. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
14 September 2015 at 7:00 AM EDT
Summary ToggleProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment
LEIDEN, the Netherlands , Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that PQ-010-002 is open for enrollment.
19 August 2015 at 8:00 AM EDT
Summary ToggleProQR Announces Results for the Second Quarter of 2015
LEIDEN, the Netherlands , Aug. 19, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
26 June 2015 at 7:54 AM EDT
Summary ToggleProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients
LEIDEN, the Netherlands , June 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
16 June 2015 at 7:01 AM EDT
Summary ToggleProQR to Present at the JMP Securities Life Science Conference
LEIDEN, the Netherlands , June 16, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
21 May 2015 at 7:01 AM EDT
Summary ToggleProQR Therapeutics Announces Results for the First Quarter of 2015
LEIDEN, the Netherlands , May 21, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
29 April 2015 at 7:00 AM EDT
Summary ToggleProQR Therapeutics Announces Annual Shareholder Meeting
LEIDEN, the Netherlands , April 29, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
29 April 2015 at 7:00 AM EDT
Summary ToggleProQR to Present at Two Upcoming Investor Conferences in May
LEIDEN, the Netherlands , April 29, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
26 February 2015 at 7:01 AM EST
Summary ToggleProQR Therapeutics Announces Results for the Fourth Quarter and Full Year 2014
LEIDEN, Netherlands , Feb. 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
4 February 2015 at 7:01 AM EST
Summary ToggleProQR to Present at the 2015 Leerink Global Healthcare Conference
LEIDEN, The Netherlands , Feb. 4, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
24 November 2014 at 7:01 AM EST
Summary ToggleProQR Therapeutics Announces Results for the Third Quarter of 2014
LEIDEN, the Netherlands , Nov. 24, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
23 September 2014 at 1:38 PM EDT
Summary ToggleProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
LEIDEN, The Netherlands , Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
18 September 2014 at 8:07 AM EDT
Summary ToggleProQR Announces Pricing of Initial Public Offering
LEIDEN, Netherlands , Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.